The use of HER2 evaluation guidelines developed in GE cancer for CRC, again, has similar advantages to breast cancer guidelines, as it can be performed by any approved IHC assay while also evaluating basolateral membrane HER2 expression. This evidence concerns the gene ERBB2 and breast carcinoma.